# Fulgent Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/FLGT/fulgent-reports-first-quarter-2026-financial-results
Ticker: FLGT
Company: Fulgent Genetics, Inc.
Source: Fulgent Genetics, Inc.
Published: 2026-05-01 11:00 EST
Original Source URL: https://ir.fulgentgenetics.com
## Summary

Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross

## Article Body
Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross
## Recent Company News
- 2026-06-01 23:00 EST — [Fulgent Presents Updated FID-007 Data at ASCO 2026](https://biopharmsignal.com/news/FLGT/fulgent-presents-updated-fid-007-data-at-asco-2026) — Source: Fulgent Genetics, Inc.
- 2026-05-21 21:03 EST — [Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting](https://biopharmsignal.com/news/FLGT/fulgent-announces-rapid-oral-full-abstract-publication-for-fid-007-within-the-head-and-neck-cancer-track-session-at-the-asco-2026-annual-meeting) — Source: Fulgent Genetics, Inc.
- 2026-05-01 11:00 EST — [Fulgent Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/FLGT/fulgent-reports-first-quarter-2026-financial-results) — Source: Fulgent Genetics, Inc.
- 2026-04-22 20:05 EST — [Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/FLGT/fulgent-selected-to-present-rapid-oral-abstract-within-the-head-and-neck-cancer-track-session-at-the-2026-asco-annual-meeting) — Source: Fulgent Genetics, Inc.
- 2026-04-16 11:30 EST — [Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026](https://biopharmsignal.com/news/FLGT/fulgent-to-announce-first-quarter-2026-financial-results-on-friday-may-1-2026) — Source: Fulgent Genetics, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)